Design Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

DSGN$10.21+5.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and par value data)

	March 31,	December 31,
	2025	2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$13,667	$22,563
Investment securities	216,007	222,914
Prepaid expenses and other current assets	3,970	2,563
Total current assets	233,644	248,040
Property and equipment, net	1,377	1,410
Right-of-use asset, related party	2,027	2,216
Other assets	427	427
Total assets	$237,475	$252,093
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$3,180	$2,186
Accrued expenses and other current liabilities (including related party amounts of $821 and $800, respectively)	5,056	6,276
Total current liabilities	8,236	8,462
Operating lease liability, net, related party	1,320	1,534
Total liabilities	9,556	9,996
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2025 and December 31, 2024; 56,768,678 and 56,754,341 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	6	6
Additional paid-in capital	472,392	468,830
Accumulated deficit	(244,929)	(227,214)
Accumulated other comprehensive income	450	475
Total stockholders’ equity	227,919	242,097
Total liabilities and stockholders’ equity	$237,475	$252,093

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.